menu
    • menu
    [{"orgOrder":0,"company":"TearSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Lacripep","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"TearSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TearSolutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TearSolutions \/ Undisclosed"},{"orgOrder":0,"company":"TearSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Series B Financing","leadProduct":"Lacritin","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"TearSolutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TearSolutions \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TearSolutions \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by TearSolutions

    Menu

    TearSolutions

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TearSolutions

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            TearSolutions

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacritin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $3.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            TearSolutions Secures $3M Series B Funding

                            Details : The proceeds will accelerate company's programs for rare corneal diseases at preclinical and clinical stages, including Lacripep, derived from the Lacritin protein, a first-in-class topical therapy.

                            Product Name : Lacripep

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : Lacritin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $3.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TearSolutions

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            TearSolutions

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lacripep

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

                            Details : Lacripep is a Peptide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Sjogren's Syndrome.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            July 21, 2017

                            Lead Product(s) : Lacripep

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth